Study to Evaluate the Safety and action of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis To evaluate the safety and tolerability of etelcalcetide after single dose administration to paediatric subjects aged 2 to less than 18 years with secondary hyperparathyroidism (sHPT) receiving mainte...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates The primary objective of this study is to evaluate if the effect of administering denosumab (60 mg subcutaneously [SC] every 6 months [Q6M]) is not inferior to that of zoledronic acid (5 mg intraveno...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Pembrolizumab (MK 3475) With Talimogene Laherparepvec or placebo in Unresectable Melanoma Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in subjects with previously untreated, unresec...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study comparing the use of etanercept and methotrexate, used either alone or in combination for the treatment of Psoriatic Arthritis To evaluate the efficacy of etanercept plus methotrexate therapy and etanercept monotherapy compared to methotrexate monotherapy, in subjects with psoriatic arthritis as measured by the proportion of...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to assess the tolerability and efficacy of AMG 145 in patients with heterozygous familial hypercholesterolemia To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145, compared with placebo SC, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in subjects with heterozygous...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to assess the tolerability and efficacy of AMG-145 monotherapy in patients with hypercholesterolemia To evaluate the effect of 12 weeks of subcutaneous AMG 145 every-2-weeks (Q2W) or every-4-weeks (Q4W), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LD...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of the Effects of AMG 334 to Prevent Migraine Headaches To evaluate the effect of AMG 334 compared to placebo on the change from baseline in mean monthly migraine days, in subjects with episodic migraine

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Clinical phase 2 study to investigate the safety and efficacy of Blinatumomab in adult subjects with newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) after treatment with standard of care R-Chemotherapy. Estudio clínico de fase II que investiga la seguridad y la eficacia de blinatumomab en pacientes adultos con diagnóstico reciente de linfoma B difuso de células grandes (DLBCL) de alto riesgo después de quimioterapia-R de primera línea To evaluate the safety of blinatumomab administered after frontline R-chemotherapy in newly diagnosed subjects with high-risk DLBCL. evaluar la seguridad de blinatumomab administrado después de ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Brodalumab in Subjects with Psoriatic Arthritis To evaluate the efficacy of brodalumab, (210 mg every 2 weeks (Q2W); and 140 mg Q2W) compared to placebo, in subjects with psoriatic arthritis, as measured by the proportion of subjects achieving an A...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and the Results of Stopping and Restarting Brodalumab Treatment in People with Moderate to Severe Plaque Psoriasis: AMAGINE-1 Compared with placebo: - To evaluate the efficacy of brodalumab (210 mg every 2 weeks [Q2W]; and 140 mg Q2W) in subjects with moderate to severe plaque psoriasis, as measured by the proportion of sub...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune